comparemela.com

Latest Breaking News On - Company assay kit - Page 1 : comparemela.com

Applied DNA and Northwell Health Establish SARS-CoV-2 Mutation and Variant Tracking Program

Published: Apr 07, 2021    - Program Powered by Applied DNA’s Mutation-targeted qPCR Assays and NGS Platform - - Program Data Potentially Relevant to COVID-19 Vaccine and Therapeutics Developers, Precision Medicine -   STONY BROOK & NEW HYDE PARK, N.Y. (BUSINESS WIRE) Applied DNA Sciences, Inc.. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and Northwell Health (Northwell) today announced their entry into a pro bono Material Transfer Agreement (MTA) that establishes a real-time surveillance program for the tracking and identification of SARS-CoV-2 mutations and variants of concern (VoCs) in Northwell’s COVID-positive specimens (the “Program”). Under the Program, de-identified positive COVID-19 specimens supplied by Northwell are being screened for SARS-CoV-2 mutations found in currently known VoCs using Applied DNA’s Linea

Applied DNA Sciences (APDN) and Northwell Health Establish SARS-CoV-2 Mutation and Variant Tracking Program

Applied DNA Sciences (APDN) and Northwell Health Establish SARS-CoV-2 Mutation and Variant Tracking Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Applied DNA Sciences, Inc : U S FDA Lists Applied DNA s Linea COVID-19 Assay Kit as 1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U K Variant (B 1 1 7)

(2) - Early and Cost-Effective Identification of Samples Potentially Containing the B.1.1.7 or Other Variants May Help Reduce Further Spread of Infection - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company ), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that the U.S. Food and Drug Administration (FDA) published a safety communication (the Communication ) that identifies the Company s Linea COVID-19 Assay Kit (the Assay Kit ) as one of only two tests marketed under the FDA s Emergency Use Authorization (EUA) that are potentially able to identify certain SARS-CoV-2 mutations, including a mutation found in the U.K. variant of SARS-CoV-2 (B.1.1.7). According to recent publications, the B.1.1.7 variant has been identified within the United States and may be associated with an increased risk of transmission of the virus that causes COVID-19. The identification of certain mutations can help identify samples that should be further characteriz

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.